Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals are limited. This phase 2, randomised, double-blind, placebo-controlled trial included healthy or medically stable individuals aged 18–85 years enrolled at two clinical...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Lancet regional health. Western Pacific Ročník 29; s. 100586
Hlavní autoři:	Hui, Ai-Min, Li, Jingxin, Zhu, Li, Tang, Rong, Ye, Huayue, Lin, Mei, Ge, Lei, Wang, Xiyuan, Peng, Fuzhong, Wu, Zhenggang, Guo, Xiling, Shi, Yunfeng, Pan, Hongxing, Zhu, Jiahong, Song, Zhizhou, Qiu, Jingjun, Wang, Wei, Zheng, Jianfei, Ozhelvaci, Orkun, Shpyro, Svetlana, Bushway, Meghan, Derhovanessian, Evelyna, Kühnle, Marie-Cristine, Luxemburger, Ulrich, Muik, Alexander, Shishkova, Yoana, Khondker, Zakaria, Hu, Simin, Lagkadinou, Eleni, Şahin, Uğur, Türeci, Özlem, Zhu, Fengcai
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Elsevier Ltd 01.12.2022 Elsevier
Témata:	BNT162b2 mRNA vaccine COVID-19 Internal Medicine Intramuscular injection Messenger RNA Neutralising antibodies Public Health SARS-CoV-2 Vaccination BNT162b2 mRNA vaccine COVID-19 SARS-CoV-2 Messenger RNA Vaccination Intramuscular injection Neutralising antibodies
ISSN:	2666-6065, 2666-6065
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!